Introduction
The transmissible spongiform encephalopathies (TSEs), which include human Creutzfeldt-Jakob disease (CJD), chronic wasting disease (CWD) of cervids, and bovine spongiform encephalopathy (BSE), are a group of closely related fatal neurodegenerative conditions caused by prions, which are defined as proteinaceous infectious particles that lack informational nucleic acid (Prusiner, 1982) . The mechanism of prion replication is unique and features the accumulation of the scrapie isoform of the prion protein (PrP), referred to as PrP Sc , which is a conformationally altered, beta-sheet-rich version of the benign host-encoded form of PrP referred to as PrP C . This post-translational structural transition is accompanied by changes in the physicochemical properties of PrP. Most notably, while PrP C is sensitive to proteinase K (PK), enzymatic treatment of full-length PrP Sc , referred to as rPrP Sc (Tremblay et al, 2004) , generates a core molecule consisting predominantly of residues 89-230, referred to as PrP 27À30 (Oesch et al, 1985) .
Approximately 10-20% of human prion diseases are familial with an autosomal dominant mode of inheritance resulting from mutations in the coding sequence of the human PrP gene (PRNP). Gerstmann-Sträussler Scheinker (GSS) syndrome, which is characterized clinically by ataxia and dementia and neuropathologically by the deposition of PrP amyloid, most commonly results from mutation at codon 102 of PRNP resulting in the substitution of leucine (L) for proline (P) (Hsiao et al, 1989) . GSS linked to this mutation is transmissible to non-human primates (Brown et al, 1994) , wild-type mice (Tateishi and Kitamoto, 1995) , transgenic (Tg) mice expressing a chimeric mouse-human PrP gene expressing the GSS mutation (Telling et al, 1995) , and Prnp genetargeted mice referred to as 101LL (Manson et al, 1999) .
To understand how an inherited disease could be infectious, Tg mice expressing mouse PrP (MoPrP) with the equivalent GSS mutation at codon 101, referred to as MoPrP-P101L, were produced. Tg mice overexpressing MoPrP-P101L spontaneously developed central nervous system (CNS) dysfunction and reproduced the neuropathological features of GSS (Hsiao et al, 1990; Telling et al, 1996a) . Brain material from such spontaneously sick mice induced disease in inoculated Tg mice expressing lower levels of mutant protein, referred to as Tg196 mice (Hsiao et al, 1994; Telling et al, 1996a) . Disease was also induced in Tg196 mice by a mutant synthetic peptide comprising MoPrP residues 89-103 refolded into a beta-sheet conformation (Kaneko K, 2000) and this disease was subsequently propagated to additional Tg196 mice (Tremblay et al, 2004) .
Such studies lent strong support to the prion hypothesis since they suggested that pathogenic PrP gene mutations resulted in the spontaneous formation of PrP Sc and de novo production of prions (Cohen et al, 1994) . However, this explanation met with controversy for several reasons (Chesebro, 1998) . Although PrP Sc produced by different prion strains has been shown to vary considerably in its resistance to proteases (Bessen and Marsh, 1992) , and protease-sensitive forms of PrP Sc (sPrP Sc ) have subsequently been identified using biochemical and immunological methods (Safar et al, 1998; Tzaban et al, 2002) , the lack of rPrP Sc in the brains of spontaneously sick or recipient mice eliminated a property that, to some, was synonymous with prion infectivity. Moreover, Prnp gene-targeted 101LL mice expressing MoPrP-P101L failed to develop neurodegenerative disease spontaneously (Manson et al, 1999) . Also, disease transmission from spontaneously sick mice to wild-type mice did not occur. Finally, spontaneous disease was eventually registered in aged Tg196 mice (Kaneko, 2000; Tremblay et al, 2004) , complicating the interpretation of the original transmission experiments.
To address the apparent dissociation of prion infectivity and PrP Sc in this well-established Tg model, we sought means other than differential resistance to PK treatment to detect disease-associated forms of PrP in spontaneously sick Tg mice expressing MoPrP-P101L. In recent years, a diverse array of reagents capable of distinguishing between native PrP C and PrP Sc has been developed. These include plasminogen (Fischer et al, 2000) , anti-DNA antibodies and a DNA binding protein (Zou et al, 2004) , RNA aptamers (Rhie et al, 2003; Sayer et al, 2004) , PrP Sc -specific monoclonal antibodies (Mabs) (Korth et al, 1997; Paramithiotis et al, 2003) , and motif-grafted antibodies containing the replicative interface of PrP C (Moroncini et al, 2004) . Although the possibility has been raised that reagents such as scrapie-specific Mabs may interact with PrP Sc aggregates through nonspecific paratopeindependent interactions (Morel et al, 2004) , the binding specificity of such interactions may be influenced by factors such as detergent extraction conditions ).
Here we demonstrate, using the prototypic PrP Sc -specific Mab 15B3, that disease in Tg mice overexpressing MoPrP-P101L results from the spontaneous conversion of mutant PrP C to protease-sensitive, 15B3-reactive MoPrP-P101L that accumulates as aggregates in the brains of sick Tg mice. We also show that MoPrP-P101L is capable of adopting at least two pathogenic, 15B3-reactive conformations that differ not only in their degree of resistance to proteolysis but also the extent to which they are endoproteolytically processed in diseased brains. To understand the influence of mutant PrP expression levels on the transmissibility of spontaneously generated pathogenic MoPrP-P101L, we produced mice in which transgene copy numbers and levels of MoPrP-P101L expression were carefully defined. While inoculation of disease-associated MoPrP-P101L accelerated disease in Tg mice expressing MoPrP-P101L from multiple transgenes, disease transmission neither occurred to wild-type nor Tg mice expressing MoPrP-P101L from two transgene copies that do not develop disease spontaneously in their natural lifespan. While these observations are not inconsistent with our current understanding of the mechanisms of nucleation-mediated prion replication, we propose that the term 'transmissibility' for this disease acceleration phenomenon is inappropriate.
Results

Detection of pathological mutant PrP in the brains of spontaneously sick Tg(GSS) mice using PrP
Sc -specific Mab 15B3 We re-established Tg mice expressing MoPrP-P101L, referred to here as Tg(GSS) mice, with a range of transgene copy numbers and MoPrP-P101L expression. As previously shown (Hsiao et al, 1994; Telling et al, 1996a) , the age of onset of spontaneous neurodegenerative disease was proportional to transgene copy number and level of transgene expression (Table I) , and spongiform degeneration, plaque deposits, and reactive astrocytic gliosis were present in the brains of mice at the time they exhibited clinical signs of neurological disease (data not shown).
Western blot analysis confirmed the results of previous studies (Hsiao et al, 1994; Telling et al, 1996a ) that brain homogenates from spontaneously sick Tg(GSS) mice did not contain rPrP Sc (Supplementary Figure 1A , lanes 6 and 8). Titration of PK concentrations ranging from 20 to 0.005 mg/ml demonstrated that mutant and wild-type MoPrP were equally sensitive to PK at concentrations greater than 0.04 mg/ml (data not shown). In addition, there was no difference in the solubility in nondenaturing detergents of MoPrP-P101L or its cleavage products, the majority of mutant PrP in the brains of both sick and healthy Tg(GSS)22 mice being soluble (Supplementary Figure 1B) .
Immunoprecipitation of PrP Sc from brain extracts of sick wild-type FVB mice inoculated with the mouse-adapted Rocky Mountain Laboratories (RML) isolate of scrapie prions but not from brains of uninfected FVB mice confirmed the previously demonstrated specificity of Mab 15B3 for PrP Sc ( Figure 1A , lanes 1 and 5) (Korth et al, 1997) . Mab 15B3 also specifically immunoprecipitated mutant MoPrP-P101L from brain homogenates of spontaneously sick Tg(GSS)22 mice ( Figure 1A , lane 11) but not from brain homogenates of healthy Tg(GSS)22 mice killed at younger ages ( Figure 1A , Figure 1A , lane 9). Mab 15B3 also failed to immunoprecipitate PrP in brain homogenates from uninfected Tga20 mice, which overexpress wild-type MoPrP ( Figure 1A , lane 7) (Fischer et al, 1996) . In additional control experiments, an unrelated isotype-matched Mab coupled to anti-mouse IgM-coupled magnetic beads failed to immunoprecipitate PrP from the same brain extracts (data not shown).
Longitudinal analyses of two independent birth cohorts of Tg(GSS)22 mice showed that the kinetics of pathological MoPrP-P101L accumulation in brain extracts of Tg(GSS)22 mice killed at different ages was remarkably reproducible ( Figure 1B and C) . While Mab 15B3-reactive MoPrP-P101L could be detected in the brains of Tg(GSS)22 mice just prior to the onset of clinical symptoms, substantial quantities did not accumulate until mice were clinically sick. In contrast, Western blotting using Mab 6H4 showed that expression of total MoPrP-P101L remained constant over the same time period ( Figure 1D ). 
Characterization of MoPrP
Spontaneous disease in Tg(GSS) mice correlates with the accumulation of 15B3-reactive MoPrP-P101L. (A) Brain extracts were treated with anti-mouse IgM-coupled magnetic beads in the presence or absence of Mab 15B3 as indicated and immunoprecipitates were analyzed by SDS-PAGE and Western blotting as described. Lanes 1 and 2, uninoculated FVB mouse; lanes 3 and 4, Prnp 0/0 mouse; lanes 5 and 6, FVB mouse inoculated with mouse-adapted RML scrapie prions; lanes 7 and 8, asymptomatic Tga20 mouse; lanes 9 and 10, asymptomatic Tg(GSS)2 mouse killed at 572 days of age; lanes 11 and 12, spontaneously sick Tg(GSS)22 mouse killed at 188 days of age; lanes 13 and 14, asymptomatic Tg(GSS)22 mouse killed at 30 days of age. (B, C) Kinetics of disease-associated MoPrP-P101L accumulation in Tg(GSS)22 mice. Brain tissues were collected from two independent birth cohorts of Tg(GSS)22 mice killed at various ages, as indicated. The second cohort of Tg(GSS)22 mice was established approximately 1 year after the first. Brain extracts were treated with anti-mouse IgM-coupled magnetic beads in the presence or absence of Mab 15B3 as indicated and immunoprecipitates were analyzed by SDS-PAGE and Western blotting using HRP- mice by density gradient sedimentation followed by immunoprecipitation. Mab 15B3 immunoprecipitated PK-sensitive MoPrP-P101L in fractions 5-12 derived from the brains of spontaneously sick Tg(GSS)22 mice with peak levels occurring in fractions 7-9 ( Figure 2E ); as expected, 15B3-immunoprecipitable MoPrP-P101L was absent from the corresponding fractions derived from brain extracts of healthy Tg(GSS)22 mice ( Figure 2F ). Mab 15B3-reactive material was also not detected in fractions from uninfected healthy Tga20 mice ( Figure 2G ). The sedimentation profile of Mab 15B3-reactive rPrP Sc in gradients prepared from RML-infected FVB mice coincided with the distribution of 15B3-reactive MoPrP-P101L in fractions isolated from the brains of spontaneously sick Tg(GSS)22 mice ( Figure 2H ), demonstrating similar aggregation states of these protease-sensitive and -resistant forms of disease-associated PrP.
Different populations of immunoprecipitable PrP were recognized by Mabs 6H4 and 15B3. The majority of 6H4-immunoprecipitable PrP was confined to fractions 1-3 and, although the relative levels of Mab 6H4-reactive PrP differed between the overexpressing Tg and wild-type FVB mice, this distribution remained constant in spontaneously sick as well as healthy Tg(GSS)22 mice ( Figure 2A and B), uninfected Tga20 mice ( Figure 2C ), and sick RML-infected FVB mice ( Figure 2D ), demonstrating that the 6H4-immunoprecipitable material corresponded to PrP C .
Inoculation of disease-associated MoPrP-P101L accelerates the age of onset of disease in Tg(GSS) mice
The lack of transmission of brain homogenates from spontaneously sick Tg(GSS)22 mice to wild-type mice (Supplementary Table I ) confirmed previous observations (Hsiao et al, 1994; Telling et al, 1996a) . Since gene-targeted 101LL mice expressing MoPrP-P101L at physiological levels failed to develop disease spontaneously (Manson et al, 1999) , we produced Tg(GSS)2 mice that express equivalent MoPrP-P101L levels from two transgene copies. Since Tg(GSS)2 mice remained free of spontaneous neurologic disease in old age (Table I) , we reasoned that they would serve as ideal alternative recipients to wild-type mice for assessing transmission of infectivity from spontaneously sick Tg(GSS)22 mice. However, Tg(GSS)2 mice failed to develop neurologic disease following inoculation with brain homogenates from spontaneously sick Tg(GSS)22 mice killed at 166 and 188 days of age (Table I) , and 15B3-immunoprecitable material was not detected in brain homogenates of asymptomatic Tg(GSS)2 mice killed 586 days after inoculation (data not shown).
Although Tg(GSS)12 mice, which overexpress MoPrP-P101L from 12 transgene copies at levels six-fold higher than wild type, eventually develop a spontaneous neurologic disorder, we asked if illness might appear more rapidly if these animals were inoculated. The average age at which Tg(GSS)12 mice inoculated with brain extracts from spontaneously sick Tg(GSS)22 mice developed illness was between 210 and 235 days earlier than the age at which uninoculated Tg(GSS)12 mice developed signs of CNS dysfunction, representing an B45-50% decrease in lifespan (Table I) . Inoculation of Tg(GSS)22 mice at B35 days of age with a brain extract from a spontaneously sick Tg(GSS)22 mouse resulted in an B30 days (B20%) reduction in the age at which mice developed neurologic disease (Table I) . Mab 15B3-immunoprecipitable MoPrP-P101L was present in the brains of Tg(GSS)12 mice inoculated with brain material from Tg(GSS)22 mice when they exhibited disease at B220 days of age ( Figure 3A, lane 1) . In contrast, 15B3-reactive MoPrP-P101L was barely detectable in brain extracts of preclinical uninoculated Tg(GSS)12 mice killed as late as 384 days of age ( Figure 3A , lane 5).
To confirm that 15B3-precipitable MoPrP-P101L mediated accelerated disease in inoculated Tg(GSS)12 mice, Mab 15B3 immune complexes isolated from the brains of spontaneously sick Tg(GSS)22 mice were inoculated into Tg(GSS)12 mice at B35 days of age. All such inoculated Tg(GSS)12 mice developed disease B210 days following inoculation. In contrast, Tg(GSS)12 mice inoculated with uncoated beads that were incubated with diseased Tg(GSS)22 mouse brain extract or Mab 15B3-coated beads incubated with diseased Tg(GSS)22 mouse brain extract that was treated with 20 mg/ml PK following immunoprecipitation remained free of neurological disease for 4300 days. All Tg(GSS)12 mice inoculated with identically treated samples using a brain extract from an asymptomatic Tg(GSS)22 mouse killed at 29 days of age remained free of CNS disease for 4300 days.
Endoproteolytic processing of different pathological
MoPrP-P101L conformers in the brains of Tg(GSS) mice PK treatment of Mab 15B3 immune complexes confirmed the protease sensitivity of disease-associated MoPrP-P101L produced in the brains of spontaneously sick Tg(GSS) mice ( Figure 3B, lanes 4 and 8) . We asked whether MoPrP-P101L was also capable of adopting a conformation that imparted resistance to PK, by inoculating Tg(GSS) mice with mouseadapted RML scrapie prions. Tg(GSS)2 and Tg(GSS)12 mice inoculated with mouse-adapted RML scrapie prions at B35 days of age developed disease at B430 and B240 days of age (Table I) . While rPrP Sc was produced in the brains of sick RML-inoculated Tg(GSS)12 mice (Supplementary Figure 1A , lane 10), the amount was less than rPrP Sc produced in the brains of sick RML-infected FVB mice (Supplementary Figure 1A, lane 4) . Transmission experiments in wild type FVB mice indicated that the strain properties of RML prions remained unchanged following passage in Tg(GSS)12 mice (Supplementary Information, Supplementary Table I and Supplementary Figure 2) . Interestingly, the electrophoretic profile of 15B3-reactive MoPrP-P101L produced in sick Tg(GSS)12 mice was dependent on whether disease originated from spontaneously sick Tg(GSS)22 mice or RML prions ( Figure 3B ). While the molecular weight of MoPrP-P101L glycoforms in the brains of sick Tg(GSS)12 mice inoculated with brain material from spontaneously sick Tg(GSS)22 mice ranged from B29 to 35 kDa, additional lower molecular weight species extending to B21 kDa were present in the brains of Tg(GSS)12 mice inoculated with RML prions. Moreover, the profile of 15B3-reactive MoPrP-P101L in recipient Tg(GSS)12 mice was equivalent to that of disease-associated PrP in the original inocula. Removal of Asn-linked glycans from Mab 15B3 immunoprecipitates with PNGase F demonstrated that these molecular weight differences were related to variations in the endoproteolytic processing of MoPrP-P101L. Previous studies have shown that the endoproteolytic cleavage product of full-length PrP Sc appears, following deglycosylation, as an B21 kDa C-terminal fragment, referred to as C2 (Chen et al, 1995) . While full-length PrP Sc and C2 were immuonoprecipitated from brain extracts of sick RML-inoculated wild-type FVB mice or sick RML-inoculated Tg(GSS)12 mice ( Figure 3C , lanes 1 and 5). Pathological MoPrP-P101L was not endoproteolytically cleaved in the brains of spontaneously sick Tg(GSS)22 mice ( Figure 3C, lanes 3 and 7) . Tremblay et al (2004) established that an B22-24 kDa 'cold PK'-resistant, disease-specific form of PrP could be precipitated from brain extracts of sick Tg(GSS) mice using sodium phosphotungstate (NaPTA). We compared the relative specificities of Mab 15B3 and 'cold PK'/NaPTA precipitation treatment for detecting disease-associated forms of MoPrP-P101L. While the 'cold PK'-resistant B22-24 kDa fragment was precipitated from the brains of sick Tg(GSS)22 mice by NaPTA (Figure 4 , lane 8), additional 'cold-PK'-resistant 27 and 19 kDa fragments were also precipitated from the brains of sick as well as asymptomatic Tg(GSS)22 mice (Figure 4, lanes 7 and 8) . Mab 15B3 immunoprecipitation of 'cold PK'-treated, NaPTA-precipitated brain extracts demonstrated that only the B22-24 kDa fragment was derived from pathological MoPrP-P101L (Figure 4 , lanes 9 and 10). Deglycosylated but otherwise untreated brain extracts from RML-infected and uninfected wild-type FVB mice (Figure 4 , lanes 1 and 2) indicated that the B22-24 kDa fragment corresponded in molecular weight to C2, while the 27 and 19 kDa fragments corresponded to fulllength PrP and the PrP C -specific degradation product referred to as C1 (Chen et al, 1995) .
Discussion
Neurodegeneration mediated by protease-sensitive mutant PrP Despite significant advances, the notion that misfolded PrP is the sole mediator of prion disease still remains contentious (Soto and Castilla, 2004) . Since the original Tg(GSS) mice were described, the assertion that de novo production of infectious prions resulted from overexpression of misfolded mutant MoPrP-P101L has met with considerable controversy. Since the prion hypothesis contends that infectivity is associated with PrP Sc , which has been defined on the basis of its resistance to protease treatment, the absence of rPrP Sc in the brains of sick Tg(GSS) mice as well other examples of disease transmission without rPrP Sc (Lasmezas et al, 1997) suggested to some that PrP Sc may not be the transmissible component. We reasoned that it might be possible to detect diseaseassociated forms of mutant PrP in the brains of sick Tg(GSS) mice without resorting to treatment with PK using the PrP Sc -specific Mab designated 15B3 (Korth et al, 1997) . Here, we demonstrate that Mab 15B3 reacts with a diseaseassociated, protease-sensitive isoform of MoPrP-P101L, which arises from the spontaneous conversion of mutant PrP C during the course of disease in the brains of overexpressor Tg(GSS) mice.
Characterization of the biochemical properties of pathological MoPrP-P101L
We also show that MoPrP-P101L is capable of producing at least two pathogenic, 15B3-immunoprecipitable proteasesensitive or partially protease-resistant conformations and that the induced conformation depends on the original conformation of PrP Sc in the inoculum. These results are consistent with earlier studies showing that the strain-specific properties of prions are enciphered in the tertiary structure of PrP Sc (Bessen and Marsh, 1994; Telling et al, 1996b; Mastrianni et al, 1999; Korth et al, 2003) . The protease sensitivity of disease-associated MoPrP-P101L produced in spontaneously sick Tg(GSS) mice is not the result of a difference in aggregation state compared to rPrP Sc , since the sedimentation profiles of both disease-associated forms are equivalent. These results indicate that Mab 15B3 is capable of recognizing pathological aggregates composed of proteasesensitive and -resistant conformers.
In addition to differences in PK susceptibility, these two MoPrP-P101L conformers were also subject to differences in endoproteolytic processing. PrP Sc is cleaved in a process facilitated by calpains (Yadavalli et al, 2004) to form a carboxyl-terminal fragment referred to as C2, which, when deglycosylated, has the same apparent molecular mass as and digested with PNGase F; lane 6, brain extract from a sick Tg(GSS)22 mouse immunoprecipitated with Mab 15B3 and digested with PNGase F; lane 7, 'cold PK' digestion followed by NaPTA precipitation, referred to as cPK/PTA, and PNGase digestion of brain extract from an asymptomatic Tg(GSS)22 mouse; lane 8, 'cold PK' digestion, NaPTA precipitation, and PNGase digestion of brain extract from a sick Tg(GSS)22 mouse; lane 9, 'cold PK' digestion, NaPTA precipitation, Mab 15B3 immunoprecipitation, and PNGase digestion of brain extract from an asymptomatic Tg(GSS)22 mouse; lane 10,'cold PK' digestion, NaPTA precipitation, Mab 15B3 immunoprecipitation, and PNGase digestion of brain extract from a sick Tg(GSS)22 mouse. Samples were analyzed by SDS-PAGE and Western blotting using HRP-conjugated Mab 6H4. The asymptomatic Tg(GSS)22 mouse was killed at 30 days of age while the sick Tg(GSS)22 was killed at 188 days of age. The positions of protein molecular weight markers of 35.5, 28.8, and 22 kDa from top to bottom are shown. unglycosylated rPrP Sc (Chen et al, 1995) . While proteaseresistant MoPrP-P101L underwent this processing event, protease-sensitive pathological MoPrP-P101L did not ( Figure 3C) . Thus, the appearance of the C2 fragment appears to correlate with the resistance of PrP to proteolysis by PK. Under conditions of 'cold PK' digestion in vitro, we confirm that proteaseresistant fragments of MoPrP-P101L with molecular weights corresponding to C2 can be detected following precipitation with NaPTA (Tremblay et al, 2004) although Mab 15B3 immunoprecipitation appears to be more selective than NaPTA in precipitating disease-specific forms of PrP (Figure 4) .
Effect of mutant transgene expression levels on disease induction by pathological MoPrP-P101L
Another important issue addressed by the current studies relates to the influence of mutant transgene expression levels during disease propagation. The absence of spontaneous disease in Tg(GSS)2 mice is in accordance with the phenotype of 101LL gene-targeted mice (Manson et al, 1999) , which have equivalent levels of MoPrP-P101L expression. While accelerated disease was recorded in Tg(GSS)12 mice inoculated either with brain material from spontaneously sick Tg(GSS)22 mice or RML prions, Tg(GSS)2 mice were only susceptible to RML prions with incubation times 4530 days. While the lack of disease transmission from spontaneously sick Tg(GSS)22 mice to wild-type mice confirmed previous observations, the lack of transmission to Tg(GSS)2 mice was initially unexpected in light of the uniform susceptibility of Tg196 mice in previous studies (Hsiao et al, 1994; Telling et al, 1996a) . However, this apparent discrepancy is readily explained on the basis of transgene copy number and levels of mutant MoPrP-P101L expression in recipient mice. While Tg196 mice did not initially develop spontaneous neurological disease (Hsiao et al, 1994) , crossing the transgene array from a wild type to a Prnp 0/0 background (Telling et al, 1996a ) resulted in spontaneous disease in a subset of mice at B550 days of age (Kaneko K, 2000; Tremblay et al, 2004) . Tg196 mice were estimated to harbor B9 copies of mutant transgene and to express PrP at levels B2-fold higher than wild type (Hsiao et al, 1994) . The occurrence of spontaneous disease in Tg196 mice is in agreement with the behavior of Tg(GSS)6 mice that harbor B6 copies of mutant transgene and develop spontaneous disease at 59871 days (n ¼ 9/9) ( Table I) .
Our data showing that wild-type and Tg(GSS)2 mice are resistant while Tg(GSS)12 mice are susceptible to the effects of pathological MoPrP-P101L indicate that disease 'transmission' from spontaneously sick Tg(GSS) mice depends on recipient mice expressing MoPrP-P101L at levels greater than that produced by two transgene copies. Since such levels of overexpression ultimately result in spontaneous disease in older uninoculated recipients, we suggest that the phenomenon of disease 'transmission' from spontaneously sick Tg(GSS) mice might be more appropriately viewed as disease acceleration whereby inoculation of disease-associated MoPrP-P101L promotes the aggregation of precursors of pathological MoPrP-P101L that result from transgene overexpression. Such a scheme is consistent with a nucleated polymerization mechanism of prion replication originally postulated on the basis of cell-free conversion systems (Kocisko et al, 1994) and subsequently demonstrated to be the basis of prion propagation in lower eukaryotes (Uptain and Lindquist, 2002 The role of PrP overexpression in the production of synthetic mammalian prions (SMPs) (Legname et al, 2004) originating from Escherichia coli-derived recombinant MoPrP remains to be determined. While the transmission properties and protease resistance of MoPrP (89-230) SMPs are clearly different from disease-associated MoPrP-P101L, it may be significant that the Tg mice in which these SMPs were initially derived expressed MoPrP(89-231) at levels 16 times higher than normal (Table II) .
Finally, it is worth comparing the Tg(GSS) mice described in these and previous studies with Tg mice expressing a mouse PrP version of a nine octapeptide insertion associated with familial Creutzfeldt-Jakob disease (CJD), designated Tg(PG14). Tg(PG14) mice exhibit a slowly progressive neurological disorder characterized by apoptotic loss of cerebellar granule cells, gliosis but no spongiosis (Chiesa et al, 1998) . Whether the brains of sick Tg(PG14) mice contain 15B3-immunoprecipitable PrP has not yet been reported; however, in both models, mutated PrP adopts different pathologic conformations either spontaneously or following inoculation with authentic prions (Chiesa et al, 2003) . Like Tg(GSS) mice, brain homogenates from spontaneously sick Tg(PG14) mice failed to transmit disease to Tg mice that express low levels of mutated PrP and that do not become sick spontaneously. Whether differences in the state of aggregation of PG14 spon compared to MoPrP-P101L will affect its ability to accelerate disease progression in overexpressor Tg(PG14) mice remains to be determined.
Materials and methods
Production and characterization of transgenic mice
The substitution of L for P at codon 101 of the MoPrP open reading frame (ORF) was produced by oligonucleotide mismatch, polymerase chain reaction (PCR)-mediated mutagenesis. The resulting ORF The number of inoculated mice developing clinical signs of scrapie divided by the original number of mice is shown in parentheses.
cassette was cloned into the cosSHa.Tet cosmid expression vector, which was previously used to produce Tg mice expressing MoPrP-P101L (Telling et al, 1996a) . Tg founders were produced by microinjection of fertilized embryos from Prnp 0/0 knockout mice on an FVB/N background, referred to as FVB/Prnp 0/0 . Genomic DNA isolated from mouse tail biopsies was screened by transgenespecific PCR. Transgene copy numbers were determined by realtime PCR using an Applied Biosystems PRISM 7000. Amplification reaction mixtures contained 25 ml of SYBR Green Universal PCR master mix (Applied Biosystems), 5 ml of 18mM mouse PrP or control mouse actin forward and reverse primers, 5 ng of DNA template, and water to a volume of 50 ml. PCR cycling conditions were 40 cycles of 501C for 2 min, 951C for 10 min, and 601C for 1 min. Nontemplate and Prnp 0/0 knockout controls were performed in parallel. All PCR reactions were performed in triplicate. DNA copy numbers were determined using the following equation: gene copy number ¼ 2 (ÀDDCt) with (Peretz et al, 2001) or Mab 6H4 (Korth et al, 1997) were used to estimate PrP expression levels.
Preparation of brain homogenates
Brain homogenates (10% w/v) were prepared by repeated extrusion through an 18-gauge followed by a 21-gauge needle in phosphatebuffered saline (PBS) for transmission experiments, protease digestion, and Western blot analysis and in Prionics Homogenization Buffer for immunoprecipitation experiments. For immunoblot analysis, samples were cleared of cell debris by a brief low-speed centrifugation.
Sources of prion inocula
The mouse-adapted RML scrapie prion isolate (Chandler, 1961) was passaged in Swiss CD-1 mice. For transmission of neurodegeneration from spontaneously sick Tg mice, brain homogenates were prepared as described above. For inoculation studies, mice were anesthetized with a mixture of isoflurane and O 2 , and inoculated intracerebrally (i.c.) with 30 ml of 1% brain homogenate using a 26-gauge needle inserted into the right parietal lobe.
Determination of clinical symptoms
Groups of uninoculated and inoculated Tg mice were monitored thrice weekly for the development of prion disease. The date of disease was recorded as the age at onset of progressive clinical symptoms of prion disease including truncal ataxia, hind-limb paresis, loss of extensor reflex, and tail stiffening.
Analysis of PrP by immunoblotting
Total protein content from brain extracts was determined by bicinchoninic acid (BCA) assay (Pierce Biotechnology Inc., Rockford, IL). In experiments involving PK digestion of brain homogenates, sarkosyl was added to a final concentration of 2% and samples containing 50-100 mg total protein were incubated for 1 h at 371C at a PK concentration of 20 mg/ml unless otherwise stated. In experiments involving PK digestion on ice followed by NaPTA precipitation, previously published methods were followed (Tremblay et al, 2004) except that 300 mg of total protein was used instead of 1 ml of clarified 10% brain homogenate. Protease digestions were terminated by the addition of phenyl methyl sulfonyl fluoride (PMSF) to a final concentration of 2 mM. Samples were boiled in an equal volume of 2 Â nonreducing sodium dodecyl sulfate (SDS) loading buffer for 5 min and resolved by SDS-polyacrylamide gel electrophoresis (PAGE) using a 12% discontinuous gel. Proteins were electrophoretically transferred to polyvinylidene fluoride (PVDF) membranes and incubated for 10 min in 5% (w/v) nonfat milk in Tris-buffered saline containing Tween 20 (TBST), incubated with appropriate primary and secondary antibodies, developed using enhanced chemiluminescent (ECL) detection (Amersham), and exposed to X-ray film.
Immunoprecipitation
A 300 ml portion of Protein G Dynabeads (Dynal) or mouse anti-IgM Dynabeads was coated with 10 mg Mab 15B3, Mab 6H4, or the respective isotype control antibody. Fifty ml of coated Dynabeads and 5 ml of a 10% (w/v) brain homogenate were added to 1 ml of Tris-buffered saline (TBS) containing 0.3% Sarcosyl and incubated on a rotating wheel for 1 h. For PK treatment, immune complexes on beads were suspended in 50 ml PBS containing 2% sarkosyl and incubated for 1 h at 371C with 20 mg/ml PK. Digestion was terminated by the addition of PMSF to a final concentration of 2 mM. Beads were washed three times with TBS containing 0.25% Sarcosyl. For deglycosylation of immunoprecipitated PrP, beads were treated with Peptide:N glycosidase F (PNGase F) for 3 h at 371C, as specified by the supplier (New England Biolabs, Beverly, MA). Beads were suspended in 20 ml of 2Â nonreducing SDS loading buffer, heated for 5 min at 961C, and immunoprecipitated proteins were resolved by SDS-PAGE using a 12% discontinuous gel. Immunoprecipitated proteins were electrophoretically transferred to PVDF membranes and incubated for 10 min in 2% (w/v) blocking solution provided in the Advanced ECL detection kit (Amersham Biosciences, Piscataway, NJ) in TBST. Membranes were probed with Mab 6H4 conjugated to horseradish peroxidase (HRP) at a 1:5000 dilution in TBST, developed using Advanced ECL detection kit (Amersham Biosciences, Piscataway, NJ), and exposed to X-ray film.
Sucrose gradient centrifugation A 1.5 ml portion of 5, 10, 15, 20, 30, 40 , and 50% sucrose solutions prepared in PBS were loaded into centrifugation tubes adapted for the Surespin TM 630 rotor of the Discovery 90SE ultracentrifuge (Sorvall) to form a zonal gradient. Mouse brain homogenates (10% w/v) prepared in PBS were centrifuged at 50 000 g for 30 min at 41C and 200 ml of supernatant was loaded on top of the gradient and centrifuged at 100 000 g for 4 h at 41C. A total of 12 1 ml fractions were collected from the top of the gradient and proteins were precipitated by the addition of 10 volumes of ice-cold methanol. After centrifugation at 4000 g for 15 min, the pellet was dissolved in 100 ml of homogenization buffer. Aliquots (20 ml) from each fraction were immunoprecipitated using Mab 15B3 or 6H4 and analyzed by Western blotting as described above.
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